GPGI, CMPO IMPORTANT DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages GPGI, Inc. f/k/a CompoSecure, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 14 Deadline in Securities Class Action – GPGI, CMPO

Rosen Law Firm reminded GPGI/CompoSecure Class A shareholders who purchased stock between November 3, 2025 and May 6, 2026 of a September 14, 2026 deadline to seek lead-plaintiff status in an investor lawsuit. The notice signals ongoing securities-litigation risk for GPGI but provides no new allegations, damages estimate, or operating update.

Analysis

This is primarily a litigation-overhang signal rather than a new fundamental datapoint. The near-term trading impact should be limited unless the complaint produces specific evidence of disclosure failures, internal controls weakness, or a credible damages framework; plaintiff-firm deadline notices alone have low information value and often fade after the deadline. For GPGI, the more relevant market question is whether the underlying alleged conduct forces a guidance reset, audit remediation, financing constraint, or customer/partner disruption.

Over the next 1-3 months, monitor for a consolidated complaint, appointment of lead counsel, an SEC inquiry, management turnover, auditor commentary, or a reserve/accrual disclosure. These events can widen the valuation discount materially because litigation raises both expected cash costs and the equity risk premium, particularly where the company has limited free-cash-flow capacity or relies on capital markets. The downside is asymmetric if the litigation overlaps with a weak earnings print: investors may treat a missed forecast as corroboration even before merits are established.

Contrarian view: the stock may be vulnerable around the September 14 deadline only if event-driven holders mistake procedural publicity for new legal substance. If no new factual allegations, regulatory action, or financial restatement emerges by the next earnings release, a deadline-driven selloff would be more likely technical than fundamental and should not be chased. A short thesis is falsified by reaffirmed or raised guidance, clean audit/internal-control disclosures, and absence of litigation escalation through the next reporting cycle.

Key Decisions for Investors

• Do not initiate a standalone short solely on the plaintiff-deadline notice; treat GPGI as a litigation-risk watch item through its next earnings release, when the underlying operating and disclosure claims can be tested.
• For existing long exposure, reduce tactical position size or hedge with 1-3 month GPGI puts only if implied volatility remains below the expected earnings-plus-litigation event premium; avoid paying elevated post-headline volatility without a defined catalyst.
• Set escalation alerts for an SEC subpoena/inquiry, auditor resignation or material-weakness disclosure, earnings guidance reduction, or a consolidated complaint containing non-public-source allegations. Any of these would support reassessing a short position over a 3-6 month horizon.
• If GPGI declines sharply into or immediately after September 14 without a new filing, regulatory development, or estimate revision, evaluate a small mean-reversion long only after confirming liquidity and support at prior technical levels; exit on any subsequent disclosure-control or guidance deterioration.